Literature DB >> 34508588

Hyperactive HRAS dysregulates energetic metabolism in fibroblasts from patients with Costello syndrome via enhanced production of reactive oxidizing species.

Giovanna Carpentieri1,2, Chiara Leoni3, Donatella Pietraforte4, Serena Cecchetti4, Egidio Iorio4, Antonio Belardo5, Daniele Pietrucci6, Michela Di Nottia1, Deborah Pajalunga2, Francesca Megiorni7, Laura Mercurio8, Massimo Tatti2, Simona Camero9, Cinzia Marchese7, Teresa Rizza1, Valentina Tirelli4, Roberta Onesimo3, Rosalba Carrozzo1, Sara Rinalducci5, Giovanni Chillemi6, Giuseppe Zampino3, Marco Tartaglia1, Elisabetta Flex2.   

Abstract

Germline-activating mutations in HRAS cause Costello syndrome (CS), a cancer prone multisystem disorder characterized by reduced postnatal growth. In CS, poor weight gain and growth are not caused by low caloric intake. Here, we show that constitutive plasma membrane translocation and activation of the GLUT4 glucose transporter, via reactive oxygen species-dependent AMP-activated protein kinase α and p38 hyperactivation, occurs in primary fibroblasts of CS patients, resulting in accelerated glycolysis and increased fatty acid synthesis and storage as lipid droplets. An accelerated autophagic flux was also identified as contributing to the increased energetic expenditure in CS. Concomitant inhibition of p38 and PI3K signaling by wortmannin was able to rescue both the dysregulated glucose intake and accelerated autophagic flux. Our findings provide a mechanistic link between upregulated HRAS function, defective growth and increased resting energetic expenditure in CS, and document that targeting p38 and PI3K signaling is able to revert this metabolic dysfunction.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34508588     DOI: 10.1093/hmg/ddab270

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  3 in total

Review 1.  Multidisciplinary Management of Costello Syndrome: Current Perspectives.

Authors:  Chiara Leoni; Germana Viscogliosi; Marco Tartaglia; Yoko Aoki; Giuseppe Zampino
Journal:  J Multidiscip Healthc       Date:  2022-06-02

Review 2.  Inside the Noonan "universe": Literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns.

Authors:  Stefano Stagi; Vittorio Ferrari; Marta Ferrari; Manuela Priolo; Marco Tartaglia
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-18       Impact factor: 6.055

3.  A novel HRAS c.466C>T p.(Phe156Leu) variant in two patients with attenuated features of Costello syndrome.

Authors:  Suzanna Lindsey-Temple; Matt Edwards; Verena Rickassel; Theresa Nauth; Georg Rosenberger
Journal:  Eur J Hum Genet       Date:  2022-06-29       Impact factor: 5.351

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.